Satyanarayana Nyalata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Satyanarayana Nyalata has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Shiqing Xu
Texas A&M University
3 shared publications Banumathi Sankaran
Laurence Berkeley National Laboratory
2 shared publications- Benjamin William Neuman
Texas A&M University
2 shared publications Chia-Chuan D. Cho
Texas A&M University
2 shared publicationsDemonta Coleman
Texas A&M University
2 shared publicationsDorsa Rabie
Texas A&M University
2 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (9) , 4888-4896
High-Throughput Screening Identifies Covalent Inhibitors with Unique Chemistry and Binding Modes for SARS-CoV-2 Main Protease
Using an easily scalable SARS-CoV-2 main protease (MPro) substrate, high-throughput screening of ∼75,000 compounds drawn from diversity and fragment libraries was conducted. Based on screening results, 40 inhibitors were confirmed with IC50 values below 30 μM. Four hits were revalidated, and their MPro complexes were characterized by X-ray crystallography. For two inhibitors, CDI5573 and CDI8009, clear active-site electron density revealed covalent modification of Cys145, the enzyme’s catalytic cysteine. In both structures, His41 of the catalytic dyad reorients from its native hydrogen-bonding pose with Cys145 to engage in π-stacking with the inhibitors’ aromatic rings. The two covalent adducts arise from distinct chemical mechanisms. CDI5573, which is a 3-nitro-1,2,5-oxazole derivative, reacts through nucleophilic aromatic substitution (SNAr) to replace one of the nitro groups by Cys145, whereas CDI8009 undergoes nucleophilic acyl substitution to form a thioester with Cys145. Structure-guided optimization of CDI5573 yielded new analogs, including one inhibitor with an IC50 of 15 nM, placing this molecule among the most potent inhibitors developed for MPro. These findings introduce new covalent chemotypes with diverse modes of engagement for MPro, expand the accessible space for this essential viral enzyme, provide leads with the potential to complement existing COVID-19 therapeutics and mitigate viral resistance, and guide the targeting of other cysteine enzymes for drug discovery.
- 13 July 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (9) , 4888-4896
Open AccessHigh-Throughput Screening Identifies Covalent Inhibitors with Unique Chemistry and Binding Modes for SARS-CoV-2 Main Protease
Using an easily scalable SARS-CoV-2 main protease (MPro) substrate, high-throughput screening of ∼75,000 compounds drawn from diversity and fragment libraries was conducted. Based on screening results, 40 inhibitors were confirmed with IC50 values below 30 μM. Four hits were revalidated, and their MPro complexes were characterized by X-ray crystallography. For two inhibitors, CDI5573 and CDI8009, clear active-site electron density revealed covalent modification of Cys145, the enzyme’s catalytic cysteine. In both structures, His41 of the catalytic dyad reorients from its native hydrogen-bonding pose with Cys145 to engage in π-stacking with the inhibitors’ aromatic rings. The two covalent adducts arise from distinct chemical mechanisms. CDI5573, which is a 3-nitro-1,2,5-oxazole derivative, reacts through nucleophilic aromatic substitution (SNAr) to replace one of the nitro groups by Cys145, whereas CDI8009 undergoes nucleophilic acyl substitution to form a thioester with Cys145. Structure-guided optimization of CDI5573 yielded new analogs, including one inhibitor with an IC50 of 15 nM, placing this molecule among the most potent inhibitors developed for MPro. These findings introduce new covalent chemotypes with diverse modes of engagement for MPro, expand the accessible space for this essential viral enzyme, provide leads with the potential to complement existing COVID-19 therapeutics and mitigate viral resistance, and guide the targeting of other cysteine enzymes for drug discovery.
- Open Access
- 14 April 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (16) , 16985-16995
Nicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic Dyad
Anecdotal reports about smokers with low SARS-CoV-2 infection rates prompted a search for nicotine and its pyrolysis products as SARS-CoV-2 main protease (MPro) inhibitors. From this search, 3-vinylpyridine was discovered as a weak binder for the MPro S1 subsite and was used subsequently as a de novo starting point for covalent inhibitor design that quickly yielded a highly potent inhibitor, SR-A-174, with an IC50 value of 60 nM. Representing a novel class of MPro inhibitors, SR-A-174 features an N,N-diaryl-α,α-dichloroacetamide scaffold that facilitated rapid exploration of alternative covalent warheads and various N-substituents, leading to the identification of multiple inhibitors with potent antiviral activity. Eight such MPro inhibitor structures were determined, all demonstrating covalent binding to catalytic Cys145 of MPro. In six determined structures, binding is dominated by the covalent bond plus van der Waals contacts, which contrasts with the extensive hydrogen bond networks formed with peptidomimetic inhibitors such as nirmatrelvir. Strikingly, two N,N-diaryl-α,α-dichloroacetamide inhibitors exhibit an unprecedented dual covalent modification mode of the catalytic dyad, forming bonds to both Cys145 and His41 with a concomitant loss of both chlorides and displacing the inhibitors from the S1 subsite. This dyad-targeting reactivity suggests a novel route for bioconjugation of both cysteine and histidine.
- 14 April 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (16) , 16985-16995
Open AccessNicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic Dyad
Anecdotal reports about smokers with low SARS-CoV-2 infection rates prompted a search for nicotine and its pyrolysis products as SARS-CoV-2 main protease (MPro) inhibitors. From this search, 3-vinylpyridine was discovered as a weak binder for the MPro S1 subsite and was used subsequently as a de novo starting point for covalent inhibitor design that quickly yielded a highly potent inhibitor, SR-A-174, with an IC50 value of 60 nM. Representing a novel class of MPro inhibitors, SR-A-174 features an N,N-diaryl-α,α-dichloroacetamide scaffold that facilitated rapid exploration of alternative covalent warheads and various N-substituents, leading to the identification of multiple inhibitors with potent antiviral activity. Eight such MPro inhibitor structures were determined, all demonstrating covalent binding to catalytic Cys145 of MPro. In six determined structures, binding is dominated by the covalent bond plus van der Waals contacts, which contrasts with the extensive hydrogen bond networks formed with peptidomimetic inhibitors such as nirmatrelvir. Strikingly, two N,N-diaryl-α,α-dichloroacetamide inhibitors exhibit an unprecedented dual covalent modification mode of the catalytic dyad, forming bonds to both Cys145 and His41 with a concomitant loss of both chlorides and displacing the inhibitors from the S1 subsite. This dyad-targeting reactivity suggests a novel route for bioconjugation of both cysteine and histidine.
- Open Access
- 14 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Facile One-Pot Synthesis of α-Boryl Ureas and Carbamates via in situ Generated α-Boryl Isocyanates to Uncover a Potent Main Protease Inhibitor
The development of efficient synthetic methods for α-boryl ureas and carbamates is of significant interest due to their potential as drug-like scaffolds in medicinal chemistry. This study presents a novel one-pot synthesis of α-boryl ureas and carbamates via α-boryl isocyanates, generated in situ from widely available α-haloboronates. The method leverages an in situ activation of trimethylsilyl isocyanate by sodium iodide to generate a more nucleophilic isocyanate species, facilitating the formation of α-boryl isocyanates under mild conditions. The broad substrate scope and functional group tolerance of this protocol enable the synthesis of diverse α-boryl ureas and carbamates, including biologically relevant molecules and late-stage pharmaceutical derivatives. To showcase the potential of this methodology in drug discovery, an α-boryl urea analog of nirmatrelvir, a SARS-CoV-2 main protease inhibitor, was synthesized, demonstrating enhanced potency (IC50 = 12 nM) compared to nirmatrelvir. This work not only offers a streamlined, direct approach for the preparation of synthetically challenging α-boryl ureas and carbamates with broad structural diversity, but also underscores the importance of α-boryl ureas as valuable scaffolds for the development of new therapeutics.
- 14 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessFacile One-Pot Synthesis of α-Boryl Ureas and Carbamates via in situ Generated α-Boryl Isocyanates to Uncover a Potent Main Protease Inhibitor
The development of efficient synthetic methods for α-boryl ureas and carbamates is of significant interest due to their potential as drug-like scaffolds in medicinal chemistry. This study presents a novel one-pot synthesis of α-boryl ureas and carbamates via α-boryl isocyanates, generated in situ from widely available α-haloboronates. The method leverages an in situ activation of trimethylsilyl isocyanate by sodium iodide to generate a more nucleophilic isocyanate species, facilitating the formation of α-boryl isocyanates under mild conditions. The broad substrate scope and functional group tolerance of this protocol enable the synthesis of diverse α-boryl ureas and carbamates, including biologically relevant molecules and late-stage pharmaceutical derivatives. To showcase the potential of this methodology in drug discovery, an α-boryl urea analog of nirmatrelvir, a SARS-CoV-2 main protease inhibitor, was synthesized, demonstrating enhanced potency (IC50 = 12 nM) compared to nirmatrelvir. This work not only offers a streamlined, direct approach for the preparation of synthetically challenging α-boryl ureas and carbamates with broad structural diversity, but also underscores the importance of α-boryl ureas as valuable scaffolds for the development of new therapeutics.